Report of Foreign Issuer (6-k)
26 September 2019 - 10:40PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
DC 20549
Form 6-K
REPORT
OF FOREIGN PRIVATE ISSUER
PURSUANT
TO RULE 13a-16 OR 15d-16 UNDER
THE
SECURITIES EXCHANGE ACT OF 1934
For
the month of September 2019
Commission
File Number 001-38370
CollPlant
Biotechnologies Ltd.
(Exact
name of registrant as specified in its charter)
4
Oppenheimer St, Weizmann Science Park
Rehovot
7670104, Israel
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form
20-F ☒ Form 40-F ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(1): ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(7): ☐
The
text under the headings “Second Quarter 2019 Financial Results on IFRS basis”, “Second Quarter 2019 Financial
Results on Non-IFRS Basis”, the accompanying consolidated financial statements and “Forward Looking Statements”
of the press release attached to this Form 6-K are hereby incorporated by reference into the registrant’s Registration Statements
on Form S-8 (File No. 333-229163) and Form F-3 (File No. 333-229486 and 333-228054), to be a part thereof from the date on which
this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.
On
September 26, 2019, CollPlant Biotechnologies Ltd. (the “Company”) issued a press release entitled “CollPlant
Reports Second Quarter 2019 Financial Results and Provides Business Update”. In addition, on the same day, the Company issued
condensed consolidated interim financial statements (unaudited) as of June 30, 2019 together with the Company’s Operating
and Financial Review and Prospects for the same period.
Attached
hereto and incorporated by reference herein are the following exhibits:
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
COLLPLANT
BIOTECHNOLOGIES LTD.
|
|
|
|
Date:
September 26, 2019
|
By:
|
/s/
Eran Rotem
|
|
|
Name:
Eran Rotem
|
|
|
Title:
Deputy CEO and Chief Financial Officer
|
2
CollPlant Biotechnologies (NASDAQ:CLGN)
Historical Stock Chart
From Apr 2024 to May 2024
CollPlant Biotechnologies (NASDAQ:CLGN)
Historical Stock Chart
From May 2023 to May 2024